Company Overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Why Investors Should Care
Generates a return on equity of 45.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 70.2% CAGR over the past five years.
Trades at a P/E of 17.2, below the sector median of 25.9.
Maintains a net profit margin of 27.0%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $605.49M (+37.1% YoY); net profit $190.29M.
- Trailing 12 Months Year-on-year growth — revenue +21.2%, earnings -71.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 70.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 70.16% |
| 1 Year: | 21.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -71.50% |
Stock Price Performance
| 1 Year: | -35.51% |
| 6 Months: | -44.02% |
| 3 Months: | -34.84% |
| 1 Month: | +3.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)54.48 · Neutral
P/E of 17.25 is below the sector median of 25.88 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 45.2%.
- Excellent profit margin of 27.0%.
- Compounding revenue at 70.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 49.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TMDX TransMedics Group, Inc. R2K | 75.38 | 17.25 | $2.61B | 0.00% | 11.09% | 45.22% | 70.16% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.76M | 3.26M | 4.75M | - | 5.29M | 6.21M | 7.88M | - | 8.24M | 3.92M | 7.97M | - | 7.64M | 8.67M | 5.41M | 15.88M | 20.52M | 24.30M | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 924.00K | 1.18M | 2.13M | 1.50M | 2.57M | 3.33M | 4.22M | 3.74M | 4.86M | 1.91M | 5.04M | 4.83M | 4.81M | 5.59M | 3.77M | 12.10M | 14.35M | 18.11M | 28.77M | 36.74M | 40.66M | 59.96M | 69.26M | 60.84M | 88.23M | 96.59M | 84.58M | 101.16M |
| Operating Income | -4.78M | -5.16M | -3.94M | -6.36M | -5.96M | -7.71M | -7.24M | -8.69M | -8.02M | -7.86M | -4.61M | -5.90M | -6.51M | -9.87M | -11.72M | -9.37M | -9.74M | -5.54M | -2.09M | -906.00K | -28.34M | 12.42M | 12.51M | 3.92M | 27.44M | 36.57M | 23.30M | 13.30M |
| Net Income | -4.90M | -6.12M | -5.11M | -7.63M | -6.89M | -9.20M | -8.28M | -9.18M | -8.85M | -8.50M | -5.09M | -6.31M | -7.92M | -10.67M | -12.96M | -10.56M | -11.52M | -7.43M | -2.64M | -1.00M | -25.42M | 12.20M | 12.19M | 4.22M | 25.68M | 34.91M | 24.32M | 7.32M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.42 | -0.36 | -0.19 | - | -0.29 | -0.39 | -0.47 | -0.38 | -0.41 | -0.25 | -0.08 | -0.03 | -0.78 | 0.35 | 0.35 | 0.12 | 0.70 | 0.92 | 0.66 | 0.20 |
| R&D Expense | 3.46M | 3.43M | 3.27M | - | 3.88M | 4.79M | 4.94M | - | 6.22M | 3.90M | 4.16M | - | 4.53M | 6.29M | 5.16M | 7.53M | 6.71M | 6.81M | 5.87M | 8.29M | 11.13M | 11.38M | 13.86M | 14.27M | 17.16M | 15.93M | 15.26M | 24.88M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.66M | 25.84M | 28.36M | 31.39M | 93.46M | 241.62M | 441.54M | 605.49M |
| Gross Profit | 5.73M | 13.86M | 16.64M | 21.16M | 65.27M | 154.09M | 262.08M | 362.81M |
| Operating Income | -20.24M | -29.60M | -26.38M | -39.43M | -31.44M | -28.73M | 37.50M | 108.58M |
| Net Income | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M | 190.29M |
| Diluted EPS | - | - | -1.16 | -1.60 | -1.23 | -0.77 | 1.01 | 4.87 |
| R&D Expense | 13.66M | 19.87M | 18.83M | 22.30M | 26.81M | 36.05M | 55.97M | 69.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 42.16M | 105.30M | 152.03M | 134.89M | 277.15M | 706.05M | 804.08M | 1.07B |
| Total Equity | -168.72M | -192.24M | 54.65M | 103.89M | 67.85M | 187.38M | 137.20M | 228.60M | 473.10M |
| Cash & Equivalents | - | 20.24M | 20.09M | 24.58M | 25.58M | 201.18M | 394.81M | - | - |
| Long Term Debt | - | 33.67M | 34.15M | 34.66M | 35.20M | 58.70M | - | - | - |
| Total Liabilities | - | 47.88M | 50.65M | 48.13M | 67.04M | 89.77M | 568.85M | 575.47M | 595.27M |
| Current Liabilities | - | 12.55M | 16.11M | 11.88M | 23.24M | 23.66M | 54.93M | 59.91M | 89.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.98M | -32.29M | -30.27M | -28.86M | -45.82M | -13.03M | 48.80M | 192.84M |
| Investing Cash Flow | 12.31M | -60.50M | -41.60M | 29.27M | 54.51M | -193.95M | -129.30M | -59.25M |
| Financing Cash Flow | 22.06M | 92.72M | 75.55M | 1.39M | 167.93M | 400.42M | 22.87M | 16.86M |
| Capital Expenditure | -418.00K | -165.00K | -455.00K | -3.52M | -11.91M | -151.85M | -129.74M | -59.25M |
| Free Cash Flow | -26.40M | -32.45M | -30.72M | -32.38M | -57.72M | -164.88M | -80.94M | 133.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 39.1% | 53.6% | 58.7% | 67.4% | 69.8% | 63.8% | 59.4% | 59.9% |
| Operating Margin % | -138.1% | -114.5% | -93.0% | -125.6% | -33.6% | -11.9% | 8.5% | 17.9% |
| Net Margin % | -162.1% | -129.8% | -101.4% | -140.9% | -38.8% | -10.4% | 8.0% | 31.4% |
| ROE % | 12.4% | -61.4% | -27.7% | -65.2% | -19.3% | -18.2% | 15.5% | 40.2% |
| ROCE % | -68.4% | -33.2% | -18.8% | -35.3% | -12.4% | -4.4% | 5.0% | 11.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.32% | 5.29M | $400.28M |
| 2 | FMR, LLC | 14.75% | 5.10M | $385.38M |
| 3 | Vanguard Portfolio Management LLC | 5.55% | 1.92M | $145.16M |
| 4 | Vanguard Capital Management LLC | 4.28% | 1.48M | $111.78M |
| 5 | State Street Corporation | 3.82% | 1.32M | $99.78M |
| 6 | Invesco Ltd. | 3.00% | 1.04M | $78.49M |
| 7 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.72% | 939.52K | $71.05M |
| 8 | Nomura Asset Management International Inc | 2.56% | 885.84K | $66.99M |
| 9 | Goldman Sachs Group Inc | 2.51% | 866.28K | $65.51M |
| 10 | Geode Capital Management, LLC | 2.43% | 839.15K | $63.46M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TMDX
TMDX Stock Rallies As Analyst Sees 77% Upside — Here’s Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPd2UtWHhVeWczNFIyYktwaFhWdFhnZDlYbUNBNzdXY21UUF9vT2s3enpBUGRBQWk0YW9lYmtUYm5TQ3VDRUhndjh6bVZHSDY1M2FLZkhWOUZlVzRvU0RKZlhlSFV3Z2JVRTNrMXJZYlBjVE9pdTZrUWZBVUhhNWNBTF9yT3pxMFRyRmNfYz…
TransMedics Group (TMDX) CEO receives major RSU and stock option grants - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOdkRvNm5hTEpja0ZTeFN0VkRJaldjUnFPLVR6TVc4aUI5Q2lrY3ZlcXY5SmVaMk8tNW9YZmhveGt4UHJsNWVneUxMQkozb2JkRXhUSFZNcnAwR2k4Z2lZNDhkMHNzSXNhVzNXNm9lbWlFcUxIQ0ZIQzJwbzJjY211WDBFZXdmeVVUMHdQX2…
What a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock Drop - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOckJtTHVsb2t0S0pQdVItSm9hTUQ0TGJKZkdnYWJMOWthU19ZSmVxVldxMkRkOWx1RzZJWTVrcEZ6RWxsdjBxdEFBT1R3M3pXa21wVlZDVFRlQ1E2RVNLT3F6OGUwZmFCRlA2UUlhdEE0Qk9RUWx1TDFSY0lLU1o2WXBTN1duclQxdWJaU0…
TMDX Stock Rallies As Analyst Sees 77% Upside — Here’s Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQY3l2OHczQjR5aDNSbk9DYml6dTh6QWpZbm1lU0ItN0pkN21jR0phWmRwcmZucGVxR2FzMzF5a0hlRGphOFpGVWQwV1g1dmtoSU1ROXYzOVR4SlJvbkpLbi1INl91Wm9QYmpWbHBmTk9EeWVNMXpsLW50Rm9vSEJNSFdaVE9jdkVHd1BUeU…
$TMDX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNN0pWMzhHUUdWbnBfWFFGUkN0WGNJNTNVTEJ3UWd2OGoxUWhTR05uRHpqNUgyTjhwMU95UGluaTdVbHg0T0FoV0FVaTNkNVZZQnh2N0k1eU1WZTh6YTAwRDZRY2ZNdUg5Tk16bWZ3aFpFYUpDWkpyY0N1a2pkaTd0RnJ4VU9YWnBPTzJpc0…
TransMedics Group (NASDAQ:TMDX) Shares Up 6.3% - Time to Buy? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcVplcDhma2d4QXA0N3U5YWtGZXluQ2llUTltUWlDT3ZHdWRZZTZmU09FODMtQ291c3Azamtsd3pRaUlFODBtWGJ3OFhxbDhzSTZVMWQ2WjZZOC13dnY2ZUJtRFpCeXBKcVNnNl9OUXBMM3VBVUVsQ2pGc2Z4MmVQaHNUWlZaaVNScWFva2…
TMDX — Frequently Asked Questions
What is the current share price of TransMedics Group, Inc. (TMDX)?
As of 2026-07-15 16:51 PDT, TransMedics Group, Inc. (TMDX) trades at $75.38 on NasdaqGM. Its 52-week range is $62.04 to $150.42.
What is the market capitalisation of TMDX?
TransMedics Group, Inc. (TMDX) has a market capitalisation of $2.61B on NasdaqGM.
What is the P/E ratio of TMDX?
TMDX trades at a trailing price-to-earnings (P/E) ratio of 17.25. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 5.29.
What is the return on equity (ROE) of TMDX?
TMDX has a return on equity (ROE) of 45.22%. Its return on capital employed (ROCE) is 11.09%.
Is TMDX a good stock to buy?
This page provides a data-driven analysis of TransMedics Group, Inc. (TMDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.